EWA
KRYS icon

EverSource Wealth Advisors’s Krystal Biotech KRYS Stock Holding History

EverSource Wealth Advisors’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$30.5K Sell
82
-26
-24% -$7.77K ﹤0.01% 2133
2026
Q1 		$27.9K Buy
108
+33
+44% +$8.78K ﹤0.01% 2281
2025
Q4 		$18.5K Buy
75
+12
+19% +$2.53K ﹤0.01% 2436
2025
Q3 		$11.1K Buy
63
+32
+103% +$4.79K ﹤0.01% 2765
2025
Q2 		$4.26K Sell
31
-24
-44% -$3.52K ﹤0.01% 3227
2025
Q1 		$9.92K Buy
55
+32
+139% +$5.38K ﹤0.01% 2113
2024
Q4 		$3.6K Sell
23
-6
-21% -$1.06K ﹤0.01% 2486
2024
Q3 		$5.28K Sell
29
-6
-17% -$1.16K ﹤0.01% 2206
2024
Q2 		$7.3K Buy
35
+21
+150% +$3.53K ﹤0.01% 2039
2024
Q1 		$2.14K Buy
+14
New +$1.95K ﹤0.01% 2359

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

EverSource Wealth Advisors's KRYS Position: Q2 2026 in Review

EverSource Wealth Advisors reduced its Krystal Biotech (KRYS) stake by 24% in Q2 2026, selling an estimated $7.77K and leaving 82 shares worth $30.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2133.

EverSource Wealth Advisors first reported a position in KRYS in Q1 2024 and has held it in 10 quarters since. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • EverSource Wealth Advisors held 82 shares of Krystal Biotech worth $30.5K as of Q2 2026.
  • EverSource Wealth Advisors sold 26 Krystal Biotech shares in Q2 2026, an estimated $7.77K.
  • Krystal Biotech made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #2133 holding.
  • EverSource Wealth Advisors first reported a position in Krystal Biotech in Q1 2024 and has held it in 10 quarters since.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.